v3.21.2
Revenues (Tables)
 9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Disaggregation of revenue by product and by geographic area
Revenues were as follows (in millions):
Three months ended September 30,
20212020
U.S.ROWTotalU.S.ROWTotal
Enbrel® (etanercept)
$1,263 $26 $1,289 $1,289 $36 $1,325 
Prolia® (denosumab)
530 273 803 478 223 701 
Otezla® (apremilast)
495 114 609 439 99 538 
XGEVA® (denosumab)
372 145 517 363 118 481 
Neulasta® (pegfilgrastim)
360 55 415 484 71 555 
Aranesp® (darbepoetin alfa)
149 247 396 158 226 384 
Repatha® (evolocumab)
139 133 272 92 113 205 
KYPROLIS® (carfilzomib)
198 95 293 173 87 260 
Other products1,052 674 1,726 1,142 513 1,655 
Total product sales(1)
$4,558 $1,762 6,320 $4,618 $1,486 6,104 
Other revenues386 319 
Total revenues$6,706 $6,423 
Nine months ended September 30,
20212020
U.S.ROWTotalU.S.ROWTotal
ENBREL$3,270 $87 $3,357 $3,619 $105 $3,724 
Prolia®
1,569 806 2,375 1,341 673 2,014 
Otezla®
1,284 335 1,619 1,280 298 1,578 
XGEVA®
1,061 412 1,473 1,036 361 1,397 
Neulasta®
1,215 168 1,383 1,538 219 1,757 
Aranesp®
409 709 1,118 489 704 1,193 
Repatha®
421 423 844 331 303 634 
KYPROLIS®
547 277 824 527 266 793 
Other products3,059 1,974 5,033 3,164 1,652 4,816 
Total product sales(1)
$12,835 $5,191 18,026 $13,325 $4,581 17,906 
Other revenues1,107 884 
Total revenues$19,133 $18,790 
____________
(1)    Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2021 and 2020.